Psychedelic Bulletin #146: Numinus Drops Lab, Consolidates Clinics; Study Suggests DMT Safe and Effective Alongside SSRI; Preprint Calls Intracellular Theory of Psychedelic-induced Neuroplasticity Into Question; A Cole Memo for Psychedelics? Post published:September 29, 2023 Post category:Psychedelic Bulletin
Psychedelic Bulletin #145: MAPS’ Second Phase 3 Study Published; EMA’s New Draft Guideline on Depression Drug Dev Includes Psychedelics; California’s Decrim. Bill Goes to Governor Post published:September 19, 2023 Post category:Psychedelic Bulletin
Psychedelic Bulletin #144: Otsuka to Buy Mindset; Responses to FDA Draft Guidance; Cybin to Acquire Small Pharma; Usona Publishes Phase 2 Study Post published:August 31, 2023 Post category:Psychedelic Bulletin
Psychedelic Bulletin #143: Trademark Filing Reveals Potential Brand Name for MDMA; DEA “Open to Considering” Special Registration for Controlled Substances via Telemedicine; Professional Practice Guidelines for PAT; Sage’s Zuranolone Rejection Post published:August 11, 2023 Post category:Psychedelic Bulletin
Psychedelic Bulletin #142: Terran’s IP Portfolio; AMA Advocates Against Non-Medical Psychedelics; Couple Receives First Psilocybin Services in Oregon; Mass. Ballot Measure Ramps Up; NIDA and NIMH Directors Opine Post published:July 31, 2023 Post category:Psychedelic Bulletin
Psychedelic Bulletin #141: Terran’s 4-OH-DiPT Prodrug Patent App.; Generic Ketamine Appears Effective for TRD; VA/DoD Guideline Reviews Psychedelics Post published:July 17, 2023 Post category:Psychedelic Bulletin
Psychedelic Bulletin #140: Regulators Weigh in on Psychedelics; Psychedelic Biotech Strikes Big Pharma Agreement; GH Publishes 5-MeO-DMT Trial Post published:June 29, 2023 Post category:Psychedelic Bulletin
Psychedelic Bulletin #139: Kentucky Earmarks $42m for Ibogaine Studies; Reunion Announces Take-Private Deal; Compass Patents Upheld; Theories of Psychedelics’ Mechanism of Action Post published:June 14, 2023 Post category:Psychedelic Bulletin
Psychedelic Bulletin #138: Delix’s Non-Hallucinogenic Psychedelic Enters the Clinic; Arizona Earmarks $5m for Whole Mushroom Psilocybin Trials; MEPs form EU Action Group Post published:May 30, 2023 Post category:Psychedelic Bulletin
Psychedelic Bulletin #137: Oregon Approves First Psilocybin Service Centre; AMA Approves Psychedelic CPT Code; MindMed Seeks to Fend Off Proxy Contest Post published:May 8, 2023 Post category:Psychedelic Bulletin